Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NEKTAR THERAPEUTICS Director's Dealing 2018

Apr 10, 2018

32134_dirs_2018-04-09_77e096e1-087b-48a4-b313-9322703993df.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2018-04-06

Reporting Person: Doberstein Stephen K (SVP & Chief Scientific Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-04-06 Common Stock M 60000 $10.69 Acquired 127394 Direct
2018-04-06 Common Stock M 50000 $7.21 Acquired 177394 Direct
2018-04-06 Common Stock M 500 $7.21 Acquired 177894 Direct
2018-04-06 Common Stock S 110500 $91.69 Disposed 67394 Direct
2018-04-09 Common Stock M 49500 $7.21 Acquired 116894 Direct
2018-04-09 Common Stock S 49500 $96.13 Disposed 67394 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-04-06 Stock Option $10.69 M 60000 Disposed 2019-02-07 Common Stock (60000) Direct
2018-04-06 Stock Option $7.21 M 50000 Disposed 2020-02-07 Common Stock (50000) Direct
2018-04-06 Stock Option $7.21 M 500 Disposed 2020-02-07 Common Stock (500) Direct
2018-04-09 Stock Option $7.21 M 49500 Disposed 2020-02-07 Common Stock (49500) Direct

Footnotes

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This transaction was executed in multiple trades at prices ranging from $89.98 to $94.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

F3: This transaction was executed in multiple trades at prices ranging from $94.99 to $96.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.